LGR4 Activators
In the context of LGR4, a receptor linked to the Wnt/β-catenin signaling pathway, activators are primarily identified as chemicals that indirectly influence the receptor's activity by modulating related signaling pathways. These chemical activators do not directly bind or interact with LGR4 but affect the cellular environment and pathways in which LGR4 operates. Compounds like Lithium Chloride, BIO, CHIR99021, and SB-216763 are GSK-3 inhibitors that activate the Wnt/β-catenin pathway. GSK-3 (Glycogen Synthase Kinase 3) is a key negative regulator of this pathway, and its inhibition can lead to enhanced Wnt signaling. Given LGR4's role in Wnt/β-catenin signaling, these compounds may indirectly increase LGR4 activity.
QS 11 and Forskolin represent a different mechanism, with QS 11 directly activating Wnt/β-catenin signaling and Forskolin increasing intracellular cAMP levels, which can have various downstream effects, including potential modulation of LGR4-related pathways. Additionally, compounds like IWR-1, IWP-2, LGK-974, XAV-939, and JW55, while primarily acting as inhibitors of the Wnt pathway, can have complex effects in cellular signaling networks. In certain contexts, these compounds might lead to an indirect modulation of LGR4 activity, highlighting the intricate interplay within signaling pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride can activate the Wnt/β-catenin pathway by inhibiting GSK-3, potentially influencing LGR4 signaling indirectly. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
BIO is a GSK-3 inhibitor that activates Wnt/β-catenin signaling, which may indirectly enhance LGR4 activity. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR99021, a GSK-3 inhibitor, can enhance Wnt signaling, potentially affecting LGR4 activity indirectly. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB-216763 inhibits GSK-3, potentially increasing Wnt/β-catenin signaling and indirectly influencing LGR4. | ||||||
Wnt Synergist, QS11 | 944328-88-5 | sc-222417 sc-222417A | 5 mg 25 mg | $138.00 $595.00 | ||
QS 11, an activator of Wnt/β-catenin signaling, might indirectly enhance LGR4 activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, an adenylate cyclase activator, can increase cAMP levels and may indirectly influence LGR4 signaling. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
IWR-1 is a Wnt pathway inhibitor that stabilizes Axin, but in a complex signaling network, it could indirectly influence LGR4 activity. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt production, potentially impacting LGR4 activity indirectly through altered Wnt signaling. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $352.00 $1270.00 | 2 | |
LGK-974 is a Wnt signaling pathway inhibitor that may have indirect effects on LGR4 signaling by modulating pathway activity. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV-939 stabilizes Axin by inhibiting tankyrase, potentially indirectly affecting LGR4 through Wnt/β-catenin signaling modulation. | ||||||